Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paragon 28 (DE:7GQ)
FRANKFURT:7GQ
Paragon 28 (7GQ) Stock Price & Analysis
0 Followers
7GQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.10 - €15.90
Previous Close€7.5
Volume0.00
Average Volume (3M)284.00
Market Cap
€657.66M
Enterprise Value€705.64M
Total Cash (Recent Filing)$58.22M
Total Debt (Recent Filing)$110.49M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 08, 2024EPS Estimate
-€0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,951,360
10 Day Avg. Volume5
30 Day Avg. Volume284
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.65
Price to Sales (P/S)7.12
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-78.98
Forecast
1Y Price Target
€14.92Price Target Upside98.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Paragon 28 News
PremiumCompany Announcements
Paragon 28 Shares Strategic and Financial Outlook Update
Bulls Say, Bears Say
Bulls Say
First Quarter PerformanceFirst quarter revenues were $61.1 million, representing a $500,000 sequential step-up over Q4, contrary to typical seasonality and cadence, which usually sees a sequential decline.
Market PositionParagon 28 is reaching its growth stride and making headway toward profitability, all while taking share in the fastest-growing segment of the orthopedic market.
Revenue GrowthRevenue growth improved slightly to 17.4% constant currency in Q1 from 17.3% constant currency in Q4, driven by new product launches, sales force expansion, medical education, and international expansion.
Bears Say
EarningsEBITDA missed consensus.
GuidancePrior bottom-line guidance included positive EBITDA expectations for 2024, but those were not reiterated as the company paid more in commissions and to external consultants, and took advantage of some unexpected new talent available in the field.
ProfitabilityProfitability was softer than expected, as increased opex spend in the quarter resulted in a widening of adj. EBITDA loss y/y and q/q.
---
7GQ FAQ
What was Paragon 28’s price range in the past 12 months?
Paragon 28 lowest stock price was €5.10 and its highest was €15.90 in the past 12 months.
What is Paragon 28’s market cap?
Currently, no data Available
When is Paragon 28’s upcoming earnings report date?
Paragon 28’s upcoming earnings report date is Aug 08, 2024 which is in 12 days.
How were Paragon 28’s earnings last quarter?
Paragon 28 released its earnings results on May 08, 2024. The company reported -€0.165 earnings per share for the quarter, missing the consensus estimate of -€0.113 by -€0.052.
Is Paragon 28 overvalued?
According to Wall Street analysts Paragon 28’s price is currently Undervalued.
Does Paragon 28 pay dividends?
Paragon 28 does not currently pay dividends.
What is Paragon 28’s EPS estimate?
Paragon 28’s EPS estimate is -€0.15.
How many shares outstanding does Paragon 28 have?
Paragon 28 has 82,951,360 shares outstanding.
What happened to Paragon 28’s price movement after its last earnings report?
Paragon 28 reported an EPS of -€0.165 in its last earnings report, missing expectations of -€0.113. Following the earnings report the stock price went down -10.363%.
Which hedge fund is a major shareholder of Paragon 28?
Among the largest hedge funds holding Paragon 28’s share is Woodline Partners LP. It holds Paragon 28’s shares valued at 2M.
---
Paragon 28 Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.92 (98.93% Upside)
€14.92 (98.93% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.44%
12-Months-Change
Fundamentals
Return on Equity
-29.23%
Trailing 12-Months
Asset Growth
6.71%
Trailing 12-Months
Company Description
Paragon 28
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.
---
7GQ Company Deck
---
7GQ Earnings Call
Q1 2024
0:00 / 0:00
---
7GQ Stock 12 Month Forecast
Average Price Target
€14.92
▲(98.93% Upside)
Technical Analysis
Best Analysts Covering 7GQ
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-18.94%
reiterated a buy rating 3 months ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -18.94% per trade.
---